Reports Q3 revenue $14.34M, consensus $9.75M. “In the third quarter, Verrica achieved multiple commercial, corporate, scientific and regulatory milestones providing a strong foundation for future growth in YCANTH as well as significant upside potential from our late-stage clinical pipeline,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Throughout the past year, while growing adoption of YCANTH for molluscum, we have also significantly advanced our late-stage clinical programs in two of the highest unmet needs in dermatology.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial
- VRCA Earnings this Week: How Will it Perform?
- Verrica Pharmaceuticals initiated with a Buy at Lucid Capital
- Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing
- Verrica Pharmaceuticals development partner receives approval for YCANTH